SIRT2 and esophageal adenocarcinoma: A panel of three proteins (EGFR, TRIM44, and SIRT2) had been shown to determine prognosis for esophageal adenocarcinoma (EAC), and a combination of this panel and clinicopathologic features could stratify patients into subgroups with different prognosis [24]–[26].